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1. Introduction
The McKell Institute is an independent,  
not-for-profit, public policy institute dedicated to 
developing practical policy ideas and contributing 
to public debate. The McKell Institute takes its 
name from New South Wales’ wartime Premier and 
Governor–General of Australia, William McKell.
William McKell made a powerful contribution to both New South Wales and Australian 
society through significant social, economic and environmental reforms
For more information phone (02) 9113 0944 or visit www.mckellinstitute.org.au
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Any remaining errors or omissions are the responsibility of the authors.
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1. Executive Summary
Australia’s system for funding new therapies that treat rare 
diseases is in need of reform.
As recognised when the Life Saving Drug Program 
(LSDP) was established in the 1990s, there is a 
need for a fit-for-purpose process to deal with the 
funding of therapies for rare diseases in Australia. 
However in the last 4 years only two new 
therapies have been approved under 
Australia’s current program for rare disease 
therapies. One, listed on a cost minimisation 
basis in a disease area already covered by the 
scheme and the second having started their listing 
process before the Government’s last review of the 
program. Aside from these products, no new 
treatments for rare disease have successfully 
navigated the entire process for funding rare 
disease therapies since the reforms in 2010.1
Australians are not only being denied access 
to new therapies funded overseas, even when 
they are provided, they are having to wait much 
longer. When new treatments for rare conditions 
are eligible under the Pharmaceutical Benefits 
Scheme’s Highly Specialised Drug Program 
there are significant delays in patient access and 
significant access restrictions imposed. 
Analysis contained in this report finds that 
Australians are generally waiting from 2 to 
4 years longer for access to rare disease 
therapies available in comparable countries 
like the United Kingdom, Canada, Germany and 
the Netherlands.2 Some medications remain 
unavailable 8 years after becoming available 
overseas. Many rare disease therapies available 
overseas are unlikely to be available in Australia 
without policy reform.
The current funding models are no longer fulfilling 
their intended roles. Many Australians have had to 
rely on their own/family funds or compassionate 
access from pharmaceutical companies to access 
new therapies. This uncertain environment is not 
equitable and a more sustainable approach is 
required.
A new approach is needed that considers the 
full scope of rare disease management, brings 
Australia closer to international standards on 
the definitions of rare diseases and evidence 
requirements for treatments, and adopts greater 
flexibility in the assessment of cost-effectiveness.
There is no common definition of a rare disease 
across the Australian health system. The 
Therapeutic Goods Act includes a limit of 2,000 
patients for the registration of orphan drugs 
- the equivalent of approximately 1 patient in 
10,000 persons.3 This definition captures fewer 
rare diseases than in comparable countries. 
In the United States the definition is 1 in 1,500, in 
Canada and the European Union it is 1 in 2,000 
and in South Korea it is 1 in 2,500. 
This report considers current approaches 
to the funding of rare disease therapies in 
Australia and internationally, reviews the current 
and future challenges, and proposes a set of 
recommendations to guide the future development 
of rare disease policy in Australia. 
The report concludes with consideration of a new 
approach to funding therapies for rare diseases based 
on Multi-Criteria Decision Analysis (MCDA), which 
would better align with Australia’s National Medicines 
Policy and reflect international best practice.
If adopted, the recommendations will ensure more 
patients diagnosed with a rare disease will have 
access to the therapies and standard of health care 
the majority of Australians take for granted. 
2. Summary of 
Recommendations
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RECOMMENDATION 1:  
The Australian Government should develop 
a National Strategy for Rare Diseases that 
provides a holistic approach to rare disease 
management. This would cover research and 
development, regulation, diagnosis, treatment, and 
the funding of new therapies and ongoing care 
needs of patients suffering rare diseases. 
RECOMMENDATION 2:  
Australia should be mindful of international 
practice and developments when designing 
rare disease policy frameworks. This includes 
reflecting international developments in the 
definition of a rare disease, assessment processes, 
and the evidence requirements for rare disease 
therapies, to ensure that Australia is a world leader 
in rare disease therapies and medical innovation.
RECOMMENDATION 3:  
A more flexible analysis of cost-effectiveness 
should be adopted in the assessment of new 
therapies that balances other considerations 
such as equity, the rule of rescue, community 
values, patient needs and the long-term costs 
avoided as a result of access to treatment. 
Consideration should be given to using Multi-
Criterion Decision Analysis as a decision-making 
framework with decision weights based on 
community and patient values.
RECOMMENDATION 4:  
The unique nature of therapies for rare 
diseases, including small patient populations 
and the implications this has for clinical 
trials, should be recognised in the evidence 
requirements for funding. This is necessary to 
address uncertainty in current processes for the 
development and funding of rare disease therapies 
in Australia. 
RECOMMENDATION 5:  
The process for assessing new therapies 
for rare diseases should be efficient, fit-
for-purpose, transparent and informed 
by community and patient values. This is 
necessary to ensure trust and legitimacy of 
decisions about funding new therapies for rare 
diseases, that Australians have timely access to 
critical treatments, and to reflect the importance of 
medical research and innovation to the Australian 
community. 
These recommendations seek to balance the 
need for a sustainable and effective process 
for managing rare disease therapies with the 
community and social values of equity in access to 
treatment for rare diseases. 
These recommendations are proposed to guide 
Government policy on the funding of rare disease 
therapies in a manner consistent with the National 
Medicines Policy objective below.
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OBJECTIVE ONE: 
Timely access to the medicines that Australians need, at a cost 
individuals and the community can afford.
The unique nature of therapies for rare diseases, including small patient populations and the 
implications this has for clinical trials, should be recognised in the evidence requirements for funding
More flexible analysis of cost-effectiveness should be adopted that balances other considerations 
such as equity, the rule of rescue, community values, patient needs and the long-term avoided 
costs of access to treatment.
The process for assessing new therapies for rare diseases should be efficient, fit-for-purpose, 
transparent and informed by community and patient values.
OBJECTIVE TWO: 
Medicines meet appropriate standards of quality, safety and 
efficacy.
The unique nature of therapies for rare diseases, including small patient populations and the 
implications this has for clinical trials, should be recognised in the evidence requirements for funding
OBJECTIVE THREE: 
Quality use of medicines.
The Australian Government should develop a National Strategy for Rare Diseases that provides a 
holistic approach to rare disease management. 
OBJECTIVE FOUR: 
Maintaining a responsible and viable medicines industry.
The process for assessing new therapies for rare diseases should be efficient, fit-for-purpose, 
transparent and informed by community and patient values. 
Australia should be mindful of international practice and developments when setting rare disease 
policy frameworks.
THE 4 OBJECTIVES OF AUSTRALIA’S NATIONAL MEDICINES POLICY 
AND RARE DISEASE RECOMMENDATIONS
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A rare disease is a life threatening or chronically 
debilitating condition that only affects a very small 
number of people in the population. Any therapy 
developed to treat a rare disease thus only has a 
very limited number of potential patients.
Rare diseases are often life threatening or 
chronically debilitating and sufferers frequently 
have no viable treatment options. New therapies 
for rare diseases may provide the only treatment 
option for patients and therefore address an 
unmet medical need.
There is no common definition of a rare disease 
across the Australian health system. The 
Therapeutic Goods Act 1989 includes a limit of 
2,000 patients for the registration of orphan drugs 
- the equivalent of approximately 1 patient in 
10,000 persons.4 
Another definition referred to in Australia is that put 
forward by the International Conference of Rare 
Disorders (ICORD). ICORD define a rare disease 
as ‘any disorder or condition that is life-threatening 
or chronically debilitating disease which is 
statistically rare, with an estimated prevalence of 
5 in 10,000 or of similarly low prevalence and high 
level of complexity that special combined efforts 
are needed to address the disorder or condition.’5 
Although these definitions are referred to, they 
are not universally adopted within the Australian 
system and may not be reflected in the existing 
decision making framework for funding of 
therapies.
Estimates range from 5,000-8,000 known rare 
diseases. Without improved data, it is difficult 
to determine the number of people affected by 
rare diseases, but international estimates have 
suggested up to 6-8 per cent of the population 
may be affected.6 
Just as defining a rare disease is complex, so too 
is the process for approval and funding of rare 
disease therapies in Australia. 
The Life Saving Drugs Program (LSDP) provides 
one mechanism for funding new therapies that 
treat rare and life threatening conditions in 
Australia.7 In addition, some therapies for rare 
diseases are funded under the Pharmaceutical 
Benefits Scheme (PBS), including through its 
Section 100 highly specialised drug (HSD) 
program.8
The Minister for Health, the Hon Peter Dutton 
MP announced a review of the LSDP on 9 April 
2014.9 In announcing the review, the Minister 
indicated that consideration needed to be given to 
access and equity, value for money and the future 
administration of the program.
The review is timely given widespread concerns 
with the current program.
Often it is families of sufferers of rare conditions 
that end up bearing the burden of managing the 
costs of therapy and care, due to the lack of 
affordable treatments. This burden is excessive, 
and cannot be fairly managed in any way other 
3. Introduction 
A rare disease is a life threatening or chronically debilitating 
condition that only affects a very small number of people in the 
population. Any therapy developed to treat a rare disease thus 
only has a very limited number of potential patients.
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than through the insurance provided by a universal 
health system.
However, patients are finding that even where new 
therapies become available overseas, they cannot 
access them in Australia due to the high cost and 
lack of government funding. 
Patients and their families are frustrated that new 
therapies funded overseas are not being funded 
in Australia, restricting access to those with the 
means to pay themselves. Even where access is 
granted, patients experience significant delays due 
to the excessive level of red tape associated with 
the current system. 
Patients living with rare diseases do not have time 
on their side. They need access to treatments that 
can stabilise their disease and extend their life 
expectancy in a much more timely efficient manner 
than is currently experienced in this country. 
Manufacturers who have responded to 
government incentives in Australia and overseas 
for greater research into rare diseases are now 
finding that the Government is unwilling to fund 
the therapies that have been developed. This 
commercial uncertainty is placing future research 
and the marketing of existing therapies for rare 
diseases in Australia in jeopardy.
The process for listing a new therapy often 
involves making multiple submissions to 
Government, which adds to the costs of bringing 
new therapies to market and creates additional 
uncertainty for both patients and manufacturers. 
While many manufacturers have been willing to 
provide compassionate access to new therapies, 
this is usually intended to cover the period 
between registration and public reimbursement 
and not to continue indefinitely.
The Government is dealing with growing budget 
pressures, including from an ageing population. 
Public campaigns to fund new therapies for rare 
diseases add to the budget pressures, and where 
such therapies do not meet standard cost-
effectiveness criteria these decisions become 
increasingly difficult to justify in terms of the overall 
health budget. 
At the same time, the Government is looking 
to new effective therapies, including for rare 
diseases, and approaches to managing health 
costs, in order to take pressure off the health 
system. 
The new Medical Research Future Fund would 
drastically expand publicly funded research 
in Australia and could lead to new treatments 
for rare diseases. However, without a system 
to commercialise and ensure access to these 
therapies if they are developed, the fund may not 
deliver on its promise.
The current system also risks creating repeated 
scenarios of drugs being funded on the basis of 
successful media campaigns rather than on clearly 
defined and transparent criteria.
Consistent with the National Medicines Policy,10 a 
new approach is required that ensures the funding 
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of new therapies for rare diseases is underpinned 
by the principles of effectiveness, efficiency and 
equity. 
Reforms are needed to provide greater certainty 
and transparency to patients, clinicians and 
industry, reduce red tape and delays in access 
to new therapies, and ensure both equitable 
treatment of patients and the sustainability of 
government finances. 
This report sets out the current Australian policy 
for funding rare disease therapies and considers 
this in the context of Australia’s universal health 
care system. 
The international context is then explored, 
including the approach to rare disease therapies 
used in other developed countries, such as the 
United Kingdom, Canada, South Korea, Germany 
and the Netherlands. 
Current policy issues with the operation of 
Australia’s rare disease policies are then outlined, 
including budget sustainability and the impact of 
the 2010 reforms on patient access. 
Future policy challenges are also addressed, 
covering the ageing of the population and the 
impact new personalised medicines on current 
funding approaches. 
An ethical framework for developing a policy 
framework for rare diseases is then discussed. 
The report then provides an overview of the policy 
objectives to fund new therapies for rare diseases, 
and how a different approach is required to meet 
the objectives of the National Medicines Policy. 
This includes outlining the ethical issues created 
by a focus on cost-effectiveness when dealing 
with therapies for rare diseases. 
The report concludes with a proposed way 
forward, including recommended principles to 
guide the development of future rare disease 
policy in Australia.
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I am a 62-year-old, late onset Pompe patient, 
with a loving wife and daughter. I was 
diagnosed in 2002 after years of failing health.
I started receiving a treatment with a new 
innovative therapy in February 2007, under 
the International Compassionate Access 
program that had been established by the 
company which makes this drug. Prior to 
starting treatment my neurologist advised that 
we should consider this treatment a success if 
it was able to stop the progress of my Pompe 
disease, which was advancing quickly.
Before I started treatment, I was struggling to 
walk more than 10m and just getting around 
our house was a challenge. To help us gauge 
the success of the treatment my neurologist 
recommended I have an MRI scan of my 
lumbar spine before starting treatment, which  
I have continued on an annual basis since.
After about six months of fortnightly infusions 
known as Enzyme Replacement Therapy 
treatment I noticed the progress of the disease 
had stopped and I regained a little of the 
strength I had lost. Over time I was able to 
improve my walking. With some assistance I 
was able to walk 36m. Follow-up MRI scans 
confirmed the progression had stopped.
Now in 2013, six years later, I am still able to 
walk around the house but if I venture further 
I use a wheelchair. I have a family history of 
Pompe, having lost my brother who after many 
years of increasing disability, the last two years 
in intensive care, passed away at the age of 
54. Unfortunately my brother never had the 
opportunity of treatment as he was diagnosed 
long before treatment was available.
I am the president of the Australian Pompe’s 
Association. I hope that with improving 
diagnosis and treatment we can find a cure for 
Pompe disease and save other families from 
this experience.
The Australian Pompe’s Association  
www.australianpompe.com
Source: ‘The Australian Experience of Living with a Rare Disease’ Megan Fookes, 2014,  
Rare Voices Australia Ltd. Available at: http://rva.blob.core.windows.net/assets/uploads/files/
RVA%20Experience-48pp-PDF.pdf
LIVING WITH LATE ONSET POMPE’S DISEASE, NSW
Raymond’s story
Meet Raymond, also President of the Australian Pompe’s 
Association who works tirelessly with and on behalf of the 
members and families. Raymond tells his story.
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In 2013-14  
the Australian Government spent  
less than 0.21% of the health budget  
on rare disease therapies under the LSDP.11
Growth in funding of specialised rare disease therapies under the LSDP has  
been miniscule, making it a manageable component of the health program.  
Funding new therapies for rare conditions under the LSDP represents just 0.24%  
of the anticipated growth in health expenditure between 2013-14 and 2017-18.14
Rare disease treatments funded under the HSDP are similarly small 
relative to the total PBS budget, though a breakdown of costs for 
rare disease therapies is not publicly available. 
While Australia lacks a single definition for rare diseases, the Therapeutic Good Act 
definition for registration of an orphan drug applies a far tighter definition to rare 
disease that comparative countries – less than 2000 patients or the equivalent of 
1 in 10,000 persons – thus limiting access to medications relative to comparable 
countries. 
In South Korea a rare disease is one diagnosed in less than 
1 in 2,500 persons15; in Canada16 and the EU17 it is less than 
1 in 2000 persons; in the US it’s one in 1,500.18
EXPENDITURE ON RARE DISEASE THERAPIES UNDER THE LSDP OF  
$80 million12 is a tiny fraction of the  
$10.3 billion  
$64.6 billion spent on health generally.13
the Australian Government spent on  
pharmaceutical reimbursement and the
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The arguments in this report take two main forms: 
1) economic arguments, focused on the pros 
and cons of different models for allocating scarce 
resources, and 2) arguments based on community 
and patient values.
At their core, both of these kinds of arguments are 
about what we as a society value the most. They 
are, therefore, fundamentally about “ethics”.
In this section, we will briefly describe the ethical 
arguments for and against a fit for purpose process 
for rare disease therapies, with a focus on different 
understandings of “distributive justice”, i.e. different 
ideas about how to distribute healthcare benefits in 
an ethically sound manner. 
Ethical arguments in favour of a 
fit-for-purpose process for rare 
disease therapies
Those who argue for a fit-for-purpose rare disease 
process are concerned not only about maximising 
healthcare benefits for the population as a whole 
(known as horizontal equity), they are concerned 
about addressing unjust inequalities (known as 
vertical equity).
In the case of rare diseases, the relevant inequality 
is that people with rare diseases are less able 
than others to obtain the resources they need. 
Specifically, the combination of small clinical trials 
and expensive medicines (in terms of unit costs) 
make it almost impossible to demonstrate that 
medicines for rare diseases are “cost-effective” at a 
population level. 
There is therefore little, if any, chance that they will 
be funded on schemes such as the PBS. This is 
unjust because it entrenches, rather than reduces, 
inequality.19
However, cost-effectiveness is only one possible 
justification for the funding of medicines. Those 
in favour of a fit-for-purpose mechanism for rare 
diseases also note that there are a number of other 
possible moral justifications for funding, which 
are not considered systematically in mainstream 
funding processes. 
Other justifications include but are not limited to: 
1) vertical equity itself (reducing inequalities simply 
because they matter and because we can afford 
to do so), 2) compassion, 3) protection of the 
vulnerable, and 4) rescuing of those in dire need 
(the “rule of rescue”).20 
Given that these justifications are likely to be 
particularly salient when it comes to rare diseases, 
it follows that a process suited to rare diseases is 
4. An Ethical Framework 
for Funding Rare 
Disease Therapies
In this report, we argue that rare diseases are significantly different 
to more common diseases, and that a fit for purpose mechanism is 
needed for allocating resources to those with rare diseases.
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needed that is able to systematically and explicitly 
consider these justifications alongside other 
considerations.
Furthermore, those who argue for a fit-for-
purpose mechanism for rare diseases note that 
standard measures of cost-effectiveness tend to 
be based on a relatively narrow understanding of 
“effectiveness,” with an emphasis on parameters 
such as longer lifespan, improved quality of life 
(according to pre-defined criteria), and reduced 
costs to the health system. 
Less attention is paid to the broader value of 
medicines including factors such as reduced carer 
burden, “holistic” care, and predictable returns to 
the pharmaceutical industry so that it will continue 
to invest in developing needed medicines. These 
factors are all known to be important to patients 
with rare diseases, their clinicians and their carers,21 
so it makes sense to ensure a fit-for purpose 
process exists for rare disease therapies that can 
systematically broaden the notion of healthcare 
benefits to include these other factors.
Ethical arguments against a fit  
for purposes process for rare 
disease therapies
Those who argue against a fit for purpose process 
for rare disease therapies base their argument on 
the importance of maximising healthcare benefits 
for the population as a whole. Their notion of 
distributive justice, sometimes also called horizontal 
equity, is therefore a utilitarian one, aiming for the 
“greatest good for the greatest number,” rather 
than one focused on reducing unjust inequalities. 
The concern that people with this understanding 
of justice have about programs that apply specific 
criteria to rare diseases is that they divert resources 
towards a small subset of the population, to the 
detriment of the population as a whole. With a 
limited healthcare budget, the use of any resources 
for one purpose, such as rare diseases, inevitably 
creates an opportunity cost and reduces what is 
available to others.22
Those with concerns about the cost of rare 
disease therapies also note that softening evidence 
requirements in order to facilitate access is not 
always to patients’ advantage. All medicines – 
including medicines for rare diseases – can prove 
to be less effective than originally believed, and can 
have unexpected adverse effects. Patients with rare 
diseases might, therefore, be harmed if medicines 
are funded without clear evidence of efficacy and 
safety.23 
People who take this view are, therefore, generally 
supportive of the current guiding principles for 
funding on the PBS, which emphasise the need to 
demonstrate clear evidence of efficacy, safety and 
population level cost-effectiveness in order to justify 
funding.
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FIGURE 2:  
VARYING IDEAS ABOUT THE GOALS OF HEALTHCARE FUNDING
HORIZONTAL EQUITY
VERTICAL EQUITY
FIGURE 1:  
ELEMENTS OF DISTRIBUTIVE JUSTICE
The need for explicit ethical 
compromise and attention to 
procedural values
It is important to note that both “sides” of the 
argument are concerned about the same broad 
ethical principle: that of “distributive justice”.  
The difference between the two positions is not 
that one is “ethical” and the other is “unethical”. 
Rather, each has a different understanding of what 
it means to distribute healthcare benefits in a “fair” 
or “just” manner, and different ideas about what 
these benefits actually are, and how they should be 
prioritised [Figures 1 and 2]. 
While the various notions 
of justice and the different 
goals of funding clearly 
intersect, they do not overlap 
completely, and achievement 
of one goal or set of goals may 
challenge fulfillment of others.
LONGER 
SURVIVAL
ENHANCED 
QUALITY OF LIFE
DEMONSTRATED 
EFFICACY AND 
SAFETY
HOLISTIC CARE
REDUCED 
HEALTH SYSTEM 
COSTS
DISTRIBUTIVE 
JUSTICE
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Furthermore, ideas about justice and healthcare 
benefits are culturally shaped, and different 
individuals and groups will inevitably understand 
and express them in different ways. On the 
basis of what we know about public attitudes, 
it seems likely that members of the Australian 
community would value both population-level 
cost-effectiveness and the resolution of unjust 
inequality.24
Any approach to the management of rare diseases 
therefore needs to be explicit about the values 
it privileges, those it sets aside, and how these 
compromises will be accommodated. 
It also needs to satisfy a number of “procedural” 
values, such as accountability, integrity, 
transparency, inclusiveness and timeliness  
[Figure 3].25 Processes that reflect procedural 
values contribute to both the perception and 
realisation of outcomes that are considered to be 
more inclusive. Applying the procedural outcomes 
outlined below can contribute to the achievement 
of outcomes that can be more clearly understood 
and potentially accepted by stakeholders. 
FIGURE 3: PROCEDURAL VALUES
ACCOUNTABILITY
INFORMED 
& NUANCED 
DECISION-MAKING
INTEGRITY
TRANSPARENCY
TIMELINESS
COORDINATION & 
HARMONISATION
TRUSTWORTHINESS
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 OBJECTIVITY refers to the ability to manage 
one’s personal interests when making decisions. 
It should be assumed that everyone involved 
in decision-making has interests (financial or 
otherwise) that might sway their decisions. A 
sufficient degree of objectivity can, however, 
be maintained through declaration and active 
management of these interests.
 INCLUSIVENESS refers to involvement in 
decision-making of all relevant stakeholders. 
In the context of funding for rare diseases, 
these stakeholders might include patients, 
lay carers, patient advocates, clinicians, the 
pharmaceutical industry, Government, and 
taxpayers.
 TIMELINESS refers to the speed of decision-
making processes. For example, it might be 
important to coordinate regulatory decision-
making and funding decisions so that access 
is not delayed unnecessarily, and to harmonise 
decision-making processes across jurisdictions.
 ACCOUNTABILITY refers in this context 
to acknowledgment and assumption of 
responsibility for actions, decisions, policies and 
products. It also implies an obligation to report, 
explain and be responsible for the outcomes 
of the above. It is, therefore, closely related to 
transparency.
 Finally, INFORMED AND NUANCED 
DECISION-MAKING refers to the principles 
according to which decisions are made. 
Processes such as Multi-Criteria Decision 
Analysis (MCDA), which incorporate numerous 
decision criteria and also allow for weighted 
consideration of the criteria, have been 
developed in an effort to achieve this goal. 
When these procedural values are adhered to, 
then trustworthiness is maximised. Trustworthiness 
refers to behaviour that instills in external 
stakeholders the belief that decision-makers have 
their interests at heart, and, where full participation 
and transparency are not possible, can be left 
unsupervised to serve these interests. This, in turn, 
creates a sense among stakeholders that decisions 
are legitimate, even if not everyone can be satisfied 
by a particular outcome.
As with the other values illustrated above, 
procedural values will inevitably be understood and 
prioritised differently by different stakeholders. For 
example, people often disagree about who should 
represent the “consumer” voice in decision-making 
and how these consumers should be engaged.26 
Similarly, industry may have more concerns than 
other stakeholders about protecting commercially 
confidential information and may, therefore, have 
different ideas about transparency.
An overarching ethical framework
On balance, the ethical arguments in favour of 
having a fit for purposes process for rare disease 
therapies are stronger than those against it. This 
case is made further throughout this report. 
We acknowledge that the approach we 
recommend places more importance on vertical 
equity than on horizontal equity, and that this could 
potentially lead to problems if the scheme is used 
unwisely. 
We try to accommodate this by recommending 
clear parameters for a fit for purposes process 
for rare diseases, and by focusing on a number 
of procedural values such as accountability, 
transparency, integrity and trustworthiness, 
coordination and harmonisation, timeliness, and 
informed and nuanced decision-making [Figure 3].
The proposed approach is ethically justifiable and 
best suited to accommodating and balancing 
myriad social values that are at stake in the 
management of rare disease therapies.
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Australia’s system seeks to balance the principles 
of cost effectiveness, equity and universality. 
However, the principles underpinning the PBS 
do not adequately deal with drugs for rare and 
life threatening conditions, which affect a small 
proportion of the population. 
In Australia there is no single definition of a rare 
disease. The Therapeutic Goods Act does contain 
a definition of an orphan drug for the purposes 
of registration as one that has fewer than 2000 
patients. This is approximated as the equivalent 
of 1 patient in 10,000 persons.27 If applied as the 
closest available rare disease definition in Australia, 
this is a far narrower definition of rare disease when 
compared to comparable countries (Table 1). 
It can take 10 to 12 years and $2 billion to develop 
and bring a new therapy to the market.33 Because 
these costs are not directly related to the number of 
potential patients, the per-patient costs of therapies 
for rare diseases are much higher than therapies 
for more common diseases with larger patient 
populations. 
5.  Australian Context
Australia’s Pharmaceutical Benefits Scheme (PBS) is arguably at 
the forefront internationally of using health technology assessment 
(HTA) to evaluate medicines for funding. 
WHAT IS A RARE DISEASE?  
DEFINITIONS VARY AROUND THE WORLD.
Australia28 <1 in 10,000 persons
United States29 <1in 1,500 persons
Canada30 <1 in 2,000 persons
European Union31 <1 in 2,000 persons
South Korea32 <1 in 2,500 persons
TABLE 1: DEFINITIONS OF RARE DISEASE
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THE UNCERTAINTY  
OF LIVING WITH  
A RARE DISEASE
Individuals living with a rare 
disease face many obstacles 
and challenges in addition 
to living with the symptoms 
and long term prognosis of 
their disease.
First, there is uncertainty 
from delays in getting a 
correct diagnosis due to 
a lack of specialty care 
and inadequate use of 
technology.
A survey in the UK found 
that on average it takes 
5.6 years and 2 to 3 
misdiagnoses before 
a patient with a rare 
disease receives a proper 
diagnosis.34
Even after a correct 
diagnosis there is often 
not an available treatment 
or cure, making the future 
uncertain and dependent on 
a medical breakthrough.
For those for whom a 
treatment or cure is or 
becomes available there 
is further uncertainty 
as therapies are often 
prohibitively expensive and 
there is no guarantee that 
public or private insurers will 
fund them.
As a result, new drugs for rare diseases are 
generally unable to meet standard PBS cost- 
effectiveness criteria, as the unit cost of therapies 
is too high. 
While the PBS does take into account rarity of 
the disease and the rule of rescue (the moral and 
psychological imperative to rescue those in dire 
need) when setting the threshold, the cost of some 
new therapies for rare diseases mean that they will 
never meet the threshold.
For example, some new treatments for chronic 
and life shortening rare conditions can cost in the 
order of $300,000 a year for life,35 raising questions 
regarding cost effectiveness, efficiency and 
horizontal equity, discussed above in the ethical 
framework. These treatments will never meet 
standard cost-effectiveness thresholds and be 
funded under the PBS.
The catastrophic nature of many rare diseases 
also means that the impact on the families and 
carers of sufferers is high compared to many other 
diseases. These impacts are not explicitly factored 
into the standard cost-effectiveness considerations 
of the Pharmaceutical Benefits Advisory Committee 
(PBAC), underestimating the potential benefits of 
new therapies for rare conditions.
The lack of funding for therapies for rare conditions 
presents a number of policy issues:
 Individuals are denied access to lifesaving or life 
changing therapies that are deemed not cost-
effective because insufficient people have the 
same condition, thus creating and entrenching 
vertical inequity.
 Greater strain is placed on our health and 
community care services to provide support 
for people suffering from rare diseases who are 
unable to access existing therapies or benefit 
from new therapies being discovered due to 
lack of funding.
 The medicines industry is discouraged from 
researching and developing new therapies, 
reducing the effectiveness of policies to 
encourage such research, and the prospect of 
cures and treatments of rare conditions. 
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 Potential innovation spillovers from rare disease 
research into more common conditions are not 
realised, removing an important potential source 
of cost savings for the health system into the 
future.
Recognising these issues, the LSDP program was 
established in the mid 1990s to provide people 
suffering rare and life threatening diseases access 
to drugs that did not meet the standard PBS 
criteria. This program, named the Live Saving 
Drugs Program, provided an avenue for therapies 
for rare and life threatening diseases to be funded 
under Australia’s universal healthcare system.
Since then, the program has funded therapies 
primarily for rare enzyme disorders.
The program was reviewed in 2010,36 leading to a 
significant tightening of access to funding for new 
therapies and reduced transparency, leading to 
many of the current issues, discussed further in 
the following section. It is now being reviewed for a 
second time.
The review is welcomed by rare disease patients, 
their families, health experts and industry. It is an 
important opportunity to consider the future funding 
of rare disease medications and ensure Australians 
are receiving the care they need. 
It is important that this review be undertaken 
in consultation with clinicians, patients, the 
pharmaceutical industry and state governments to 
ensure the challenges that persist for rare disease 
patients and industry are met. 
In undertaking the review patients and the medical 
research and pharmaceutical industry are looking 
to government to build confidence in the process 
for rare disease therapies, critical to ensuring 
investment in research and treatment continues.
The review would also benefit from considering 
the path that many people with rare diseases must 
travel, from delays in receiving an initial diagnosis, 
to limited treatment options and meeting long term 
care needs. 
A whole of Government strategy covering 
diagnostic services, accessing and funding existing, 
new and experimental therapies and meeting long 
term care services would ensure that Australia is 
well placed to deal with rare disease management 
challenges today and into the future.37
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BRINGING A NEW 
THERAPY FOR A RARE 
DISEASES TO MARKET
Bringing a new therapy to market 
involves three distinct stages:
1. Discovery and Development
2. Registration and Marketing 
Authorisation
3. Patient Access to Medicines
In each of these stages, specific challenges 
exist in the case of new therapies for rare 
diseases. 
These add to the cost and uncertainty of 
developing new therapies. Addressing these 
issues through better regulatory practices 
will help ensure that more new therapies 
become available in the future.
DISCOVERY AND DEVELOPMENT
Research and development is more complex 
and time consuming due to the nature of 
rare diseases.
By definition there are a small number of 
patients, and many rare diseases frequently 
present with a wide variety of different 
clinical symptoms, making identification 
difficult.
Limited prior research means that the 
biology of these diseases is poorly 
understood, limiting the ability to use 
animal or computer models in research. 
This reduces the ability to fully utilise prior 
research in the discovery phase.
Once identified, developing a product 
through clinical trials is further complicated 
by small numbers of research participants, 
geographical spread and an under-
diagnosed or mis-diagnosed patient 
population. In addition, having a placebo 
controlled arm in a clinical trial creates a 
significant ethical issue where there are no 
other treatment options available to patients. 
These issues mean that gold standard 
clinical trial designs are often not feasible, 
creating issues on the acceptability of 
data from trials, which often differ across 
jurisdictions.
REGISTRATION AND MARKETING 
AUTHORISATION
Assessing new therapies for rare diseases 
is a complex process that requires highly 
specialised expertise, both in the disease 
and in the assessment processes, which 
regulators may lack. 
The need to assess data from non-standard 
trials and the difficulty in determining the 
best approach for patients who will benefit 
from a new treatment often delay final 
decisions by regulators.
PRICING AND REIMBURSEMENT
Many countries have augmented their 
conventional HTA systems to deal with 
therapies for rare diseases. While these 
alternate approaches attempt to address 
the special nature of therapies for rare 
diseases, they create a myriad of systems 
for companies to traverse globally. 
Even when approved for funding, patient 
access to therapies is often limited 
and complicated through prescription 
restrictions. This may require not only 
specialist prescription but ongoing 
evaluation of individual patient responses to 
therapies. 
Companies are often required to set up 
registries and conduct post approval studies 
to fulfil regulatory requirements. While these 
registries are important and useful, the 
different requirements across jurisdictions 
add to costs and uncertainty.
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LIVING WITH CHRONIC IDIOPATHIC 
INTESTINAL PSEUDO OBSTRUCTION 
LINKED FILAMIN A DEFECT, NSW
Chris Walker, a proud grandfather fondly 
called ‘Pop’, talks about supporting his 
grandsons who live with a very rare condition.. 
“As a hard-working Australian of Scottish heritage, 
I come from a family that has contributed to 
Australian life through exploration, the arts, sport 
and in many other ways. There have been stories of 
great success and also of rotten luck.
It was my interest in genealogy that led me to 
the diagnosis and understanding of the very rare 
disease that has affected my grandson Jordan, 
who is now four years old. He spent his first 14 
months in hospital. 
This very rare genetic disease we discovered 
was called chronic idiopathic intestinal pseudo 
obstruction linked filamin a defect, which is usually 
fatal and found in males. Research into family 
history found other similarly-affected males. I had 
to resort to putting the family tree above Jordan’s 
bed to get the doctors to pay attention to our family 
history. Even when we had a diagnosis for Jordan, 
we were unable to prevent another child being born 
with the same condition, as Logan’s mother was 
already pregnant by the time we found out. It was 
only when a medical student noticed our family tree 
on a hospital notice board that we finally got offered 
genetic testing. To this day, the two sets of medical 
teams in two different states have not spoken to 
each other. 
This disease can’t be fixed, just treated, and 
requires constant care. For Jordan, this means 
tubes to drain fluids from the small intestine from 
both sides of his abdomen and a naso-gastric tube 
hooked to a pump for fluid replacement. Causal 
vomiting is also part of the problem, along with 
the health system’s inability to be able to deal with 
the requirements of providing support to those 
caring for Jordan and Logan, who is much more 
severely affected. Caring for the boys in their own 
home involve most family members, with all of 
the additional costs being borne by the family as 
a whole. Both boys will require Total Parenteral 
Nutrition for life, as well other surgeries. 
The two boys simply don’t fit the boxes of an 
inflexible funding system. 
We know that the National Disability Insurance 
Scheme is a magnificent development, but I 
honestly don’t think we can survive until 2018 (as 
officially advised) without help. We were paying in 
the vicinity of $200-$500/week for medical supplies 
and medications. Until recently we received no 
support at all, because even charities which claim 
to be flexible have very strict guidelines and we just 
don’t fit. 
Without the wonderful support of the likes of a 
number of charities in recent months we were 
wondering how much longer we could go on. 
There was no support from either State or Federal 
governments to provide the air-conditioning for 
the boys, who are unable to regulate their body 
temperature. 
A charity stepped up and helped us with that. 
We have also been able to access support from 
other charities as well, with case management and 
funding to help with the cost of the dressings and 
medications. We are extremely grateful to them 
but it is not good enough that a family has to run a 
virtual hospital ward at home, without the help that 
is given to high profile diseases. 
Surely as Australians we can do better than this for 
those so affected by such rotten bad luck!”
Source: ‘The Australian Experience of Living with a Rare Disease’ Megan Fookes, 2014,  
Rare Voices Australia Ltd. Available at: http://rva.blob.core.windows.net/assets/uploads/files/
RVA%20Experience-48pp-PDF.pdf
JORDAN AND LOGAN’S STORY
Case Study
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The growth in the number of identifiable rare 
diseases and available treatments has presented 
governments worldwide with significant challenges 
that have been heightened by the constrained 
post-GFC budget environment.
International responses provide some guidance 
on potential approaches that might be adopted 
by the Australian Government. While approaches 
vary, almost every government has applied special 
criteria and processes for therapies for rare 
diseases reflecting an understanding that they are 
fundamentally different to other diseases.
An analysis of approval processes for rare disease 
therapies against comparable countries (Table 2) 
indicates that Australians are not only being denied 
therapies made available in other countries, but are 
also waiting much longer for access when granted. 
Based on an available sample of approvals for 
select drugs over the last 4 years, Australians 
are generally waiting anywhere from 2 – 4 
years longer for access to government 
funded treatments for rare diseases than 
in comparable countries (Table 2). Some 
medications remain unavailable 8 years after 
becoming available overseas. For some rare 
disease therapies available overseas, access may 
never be granted in Australia without policy reform.
While this delay reflects a range of factors, 
including the timing of patient trials, applications 
for approval for funding in Australia, and a relatively 
small number of therapies, the delay in access 
demonstrates the uncertainty for patients, clinicians 
and the sector in the provision of rare disease 
therapies in Australia. 
This is indicative of a system that needs reform to 
streamline the assessment process and provide 
Australians with timely access to life saving and life 
changing therapies, that they could access months 
or even years sooner if they lived in other countries. 
In this section we look at the approaches taken in 
five comparable settings: Germany, Netherlands, 
the UK, Ontario Canada and South Korea. We 
then analyse how these different approaches have 
treated each of the new therapies considered 
under the LSDP since the Australian 2010 reforms.
While the international comparison reveals 
diverse systems for managing and funding 
rare disease therapies, the evidence 
increasingly points to the need for a 
consultative process with industry, clinicians 
and patients, as well as assessing multiple 
criteria to ensure the unique elements of rare 
diseases are at the forefront of decisions 
about the funding and approval of rare 
disease therapies. 
Governments worldwide are increasingly aware of 
the inequity faced by rare disease patients where 
access to therapies are denied and of the challenge 
this presents to managing health costs, medical 
research and development, and equitable access 
to health services for all citizens. 
Governments across the world have undertaken 
various reviews, discussed below, and systems are 
being designed that better meet the challenge of 
funding rare disease therapies and better valuing 
those treatments. In undertaking the current review, 
Australia is well placed to draw on international 
experience to ensure Australian patients have 
access to world leading rare disease therapies.
6. International Context
Australia is not alone in grappling with the issues raised by 
therapies for rare diseases. 
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TABLE 2: SAMPLE OF APPROVALS FOR SELECT DRUGS 
Drug
Brand 
Name
Manufacturer Indication Australia England
Ontario 
Canada
Netherlands Germany
Miglustat Zavesca
Actelion 
Pharmaceuticals 
Australia 
Niemann-Pick type C 
Disease
Not 
Available
July 2009 Nov 2010 2009 2009
Alglucosidase 
alfa
Myozyme
Genzyme 
Australia – A 
Sanofi Company
Late onset Pompe 
disease 
Not 
Available
May 2006
June 
2009
2006 2006
Velaglucerase 
alfa, powder for 
IV infusion 
Vpriv® Shire Australia Type 1 Gaucher disease
March 
2012
Dec 2010 2010 2010
Taliglucerase alfa Elelyso Pfizer Australia Type 1 Gaucher disease
Not 
Available
Rejected* Rejected* Rejected*
Eculizumab Soliris
Alexion 
Pharmaceuticals 
Paroxysmal nocturnal 
haemoglobinuria
June 
2012
April 2009 July 2010 2007 2007
Eculizumab Soliris
Alexion 
Pharmaceuticals 
Atypical Haemolytic 
Uraemic Syndrome
Dec 2014
August 
2013
2011 2011
Sapropterin Kuvan Merck Serono Hyperphenylaninanemia Nov 2012
April 
2010
2008 2008
Ivacaftor Kalydeco
Vertex 
Pharmaceuticals
Cystic Fibrosis Dec 2014 Dec 2012
June 
2014
August 
2012
*Vpriv granted exclusive access for 10 years
NOTE: Limited data is available on the timing and listing of rare disease medications across 
jurisdictions. The above information has been collected from publicly available sources and in some 
cases pharmaceutical companies have provided data for their respective rare disease therapies in each 
jurisdiction.
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The German approach
The German government introduced wholesale 
reforms to its system of therapy reimbursement in 
2011 with the Pharmaceutical Market Restructuring 
Act.38 
Prior to the Act all new therapies were only required 
to be clinically effective to be funded. There was no 
requirement that there be a net benefit compared 
to an existing therapy from the new therapy, and 
companies could charge any price for a new drug. 
This is a very different approach to that applied in 
Australia.
The 2011 reforms introduced a tougher system of 
reimbursement and aimed to lower the growth in 
costs of pharmaceuticals and ensure that therapies 
funded were providing additional benefit. 
Under the new system therapies must demonstrate 
an additional benefit to existing drugs or be 
deemed equivalent to an existing drug and be 
subject to reference pricing.39
However, the reforms exempted orphan drugs 
which are defined as therapies with sales revenue 
of less than 50 million Euros. 
As a result, under the German system all orphan 
therapies designated by the European Commission 
are funded, as long as their total annual cost is less 
than 50 million Euros.40
This relatively straightforward approach attempts 
to strike a balance between providing patients 
with access to therapies for rare conditions, and 
ensuring budget sustainability.
The Dutch approach
On 1 January 2014 the Netherlands introduced 
reforms to its access and funding arrangements for 
therapies for rare diseases.41 
Historically, therapies for rare diseases were funded 
through the Medicines Reimbursement System or 
the hospital setting.
However, all orphan therapies authorised by the 
European Community are now reimbursed through 
a hospital setting. 
The reforms are part of a broader policy to transfer 
the provision of all specialist therapies to the 
hospital setting. 
If a physician prescribes an orphan therapy, 
hospitals are reimbursed via an add-on to the 
standard funding for the treatment of the rare 
disease.
95 per cent of the cost of the therapies on the list 
is reimbursed by the Ministry of Health, with the 
remaining 5 per cent being paid from the hospital 
budget.
This new approach is also being applied to patients 
with common conditions, such as arthritis, for 
whom specialised medicines have been developed. 
Specialised medicines may treat a specific stage 
of a disease or be administered because individual 
patients have not responded to standard therapies. 
The Dutch approach removes reimbursement 
decisions for therapies for rare diseases and 
specialised therapies completely from the 
mainstream evaluation approach. 
Instead, specialist physicians treating individual 
patients have the discretion to administer such 
therapies where they deem it clinically necessary 
and appropriate. 
Such an approach recognises that standard 
reimbursement approaches are not appropriate for 
therapies treating rare conditions. It ensures that all 
patients deemed by specialised physicians as able 
to benefit from a rare therapy have access to such 
therapies. 
This approach reduces central government control 
over the scale of spending on therapies for rare 
conditions. However, the inclusion of cost sharing 
with hospitals alleviates some of these concerns.
The Dutch system also has ability to revisit data 
over time, as was seen with Fabry and Pompe 
disease therapies in 2013.
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The English and Welsh approach
The National Institute for Health and Clinical 
Excellence (NICE) evaluates new therapies in 
England and Wales. Since 2002, it has been 
mandatory for all National Health Services 
in England and Wales to fund therapies 
recommended by NICE.
Similar to PBAC in Australia, NICE evaluates the 
cost-effectiveness of new therapies using HTA. 
NICE’s standard process considers the rarity of the 
disease being treated and availability of alternatives 
when setting an acceptable cost per quality 
adjusted life-year (QALY) threshold. For example, 
a higher threshold may be set reflecting the rare 
nature of the condition that the new therapy treats. 
Notwithstanding this, many treatments for ultra-rare 
diseases generally do not meet even these higher 
thresholds due to unit cost.
Previously, therapies for ultra-rare diseases affecting 
less than 1 per 50,000 population were considered 
by a separate specialist body, the Advisory Group 
for National Specialised Services (AGNSS), 
however these recommendations were not binding 
and were frequently ignored.42 
In April 2013, responsibility for ultra-orphan 
therapies was transferred to NICE and a separate 
process was established.
In its interim guidance, NICE has implemented 
Multi-Criteria Decision Analysis (MCDA) in its HTA 
assessment of ultra-orphan drugs, to include 
criteria beyond cost-effectiveness. Rather than an 
automatic cut off for cost-effectiveness based on 
cost per QALY, cost-effectiveness is considered 
alongside other factors.
While similar to the approach taken by the LSDP, 
the MCDA appears to provide a more rational, 
rigorous, fair and transparent framework.43 
For example, NICE considers a wider set of factors 
when undertaking HTA assessments of ultra-
orphan drugs:44
 Impact of the disease on carers’ quality of life. 
 Overall magnitude of health benefits to patients 
and, when relevant, carers. 
 Whether there are significant benefits other 
than health, including whether a substantial 
proportion of the costs or benefits are incurred 
outside the NHS and personal and social 
services.
 The potential for long-term benefits to the NHS 
of research and innovation.
The process also allows for weighted consideration 
of the criteria, unlike the LSDP where all criteria 
must be fully met in order for a new therapy to be 
recommended for funding.
The NICE is currently undertaking a full consultation 
on the new framework for evaluating rare diseases. 
A key focus of UK industry groups is the need 
consistency in definition of orphan and ultra-orphan 
diseases to better align with international standards 
and ensure greater access to treatment for rare 
diseases.45 
The Canadian approach
There are systems operating in Canada, one at the 
national level but administered by the Provinces, 
and a separate system that operates in the state of 
Ontario.
NATIONAL APPROACH
Similar to NICE and PBAC, the Canadian Agency 
for Drugs and Technologies in Health (CADTH) 
uses a cost-effectiveness framework to make 
recommendations on the funding of new therapies 
under its Common Drug Review (CDR) process. 
In May 2014 a review of the process for funding 
new treatments for rare diseases concluded that 
no separate process would be established. Instead 
minor adjustments for rare diseases are being 
considered to the current CDR process.46
Under the current system, when CADTH makes a 
determination about cost-effectiveness of a new 
therapy under the Common Drug Review process, 
individual provinces and territories decide whether 
to fund these therapies. 
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Some jurisdictions have special criteria for rare 
therapies (see detail on Ontario’s approach below) 
while others apply strict cost-effectiveness criteria. 
This creates geographical inequity across Canada 
with access to certain therapies contingent on 
where you live.
The Canadian Government is currently developing a 
broader orphan drug framework for the first time.
The framework will cover the determination of 
an orphan therapy, and its authorisation and 
monitoring. It aims to provide faster access to 
therapies for rare diseases and encourage research 
and innovation in Canada.
ONTARIO
Ontario introduced a draft Drugs for Rare Diseases 
(DRD) Framework in 2010.47 It aims to influence 
the development of the national framework with its 
experience.
The DRD framework comprises six steps:
STEP 1: Determine whether the disease is rare
STEP 2: Review the natural history of the disease
STEP 3: Assess the potential effectiveness of the 
treatment, using best available evidence
STEP 4: Evaluate total budget impact
STEP 5: Identify additional follow-up data required
STEP 6: Consider “social values” based on input 
of Ontario’s Citizens
Importantly, while considered as part of the 
process, cost-effectiveness is not the sole deciding 
factor in funding new therapies. Instead, social 
values and benefits are considered alongside 
budget impact and effectiveness in funding 
decisions.
The South Korean Approach
South Korea is a middle-income country with a 
GDP per capita less than half that of Australia. 
Despite this, South Korea has a comprehensive 
rare diseases policy that helps ensure access to 
therapies for people suffering from rare conditions.
South Korea introduced reforms to the 
reimbursement of new drug therapies at the end 
of 2006, through the Health Care System Reform 
Act. It was the first Asian country to formally use 
economic evaluation in health resource allocation 
decisions. 
The reforms introduced a positive list in response to 
rising health and pharmaceutical costs. Before the 
reforms South Korea operated a negative list and 
reimbursed over 20,000 therapies, this number has 
since been reduced to 13,000.48 
Under a negative list, the presumption is towards 
reimbursement for therapies granted marketing 
approval by the regulatory body. Under a positive 
list a case must be made for reimbursement of 
therapies following approval of market access.
Similar to Australia’s PBAC process, manufacturers 
in South Korea apply to the Health Insurance 
Assessment and Review service (HIRA) to have 
therapies reimbursed. HIRA applies standard 
health technology assessment processes, with 
manufacturers having to demonstrate both clinical 
usefulness and cost effectiveness.
However, not all new therapies have to go through 
this process. If a therapy satisfies the following 
criteria, collectively known as the ‘rules of rescue’, 
then the Department of Health automatically enters 
into price negotiation ahead of reimbursement: 
 There are no alternatives;
 It is a life threatening disease;
 It is an orphan therapy; or
 There is an overall survival improvement.
The total value of production or importation of 
the therapy must also be less than US $5 million 
annually.
Orphan therapies in South Korea are designated 
where they treat a condition or disease with less 
than 20,000 patients, or approximately 1 in 2,500 
people.  
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Lessons from overseas
A summary of the international systems considered 
in this review is provided in Table 3. 
It illustrates that Australia’s LSDP is one of the more 
stringent schemes internationally for assessment of 
funding of therapies for rare diseases. In particular 
the requirement that each of the eight criteria 
(discussed below) be met is out of step with 
international approaches utilising forms of HTA.
Table 2 above looked in more detail at the path of 
approval for new therapies since the 2010 reforms, 
and illustrates that Australians with rare diseases 
are not gaining the same access to life saving or life 
changing drugs as in other jurisdictions. 
Even where Australians are getting access to new 
therapies they are often waiting months if not years 
longer than in comparable countries.
For people living with a rare disease, such delays 
are difficult, and while many have been able to rely 
on compassionate access from pharmaceutical 
companies while submissions for funding are 
considered, such access is not guaranteed to 
continue into the future. Others are missing out 
even on access to compassionate programs.
Reforms are therefore needed to put Australians 
suffering rare conditions on the same footing as 
those suffering the same conditions overseas, and 
as Australians with more prevalent diseases.
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Basis of 
Reimbursement 
of Therapies for 
Rare Conditions 
Threshold 
for Special 
Consideration of 
Reimbursement 
for Therapies of 
Rare Conditions
Process 
for Special 
Consideration
Access to 
Approved 
Therapy
Adherence 
to principles 
of cost-
effectiveness
Adherence 
to Rule of 
Rescue
Australia Rule of rescue 
Rejection by 
PBAC for listing 
on PBS
Designation 
by TGA as an 
Orphan Therapy
PBAC 
assessment 
of whether 
new therapy 
meets each of 
8 criteria for 
funding
Special 
conditions 
for initial 
access and 
ongoing 
access
No Yes
Germany
Reasonable 
society cost of 
provision
Designated 
Orphan Therapy 
by European 
Commission; 
and
<50 million euro 
annual cost
Automatic
Through 
social health 
insurers
No Yes
Netherlands
Clinically 
determined 
need
Designated 
Orphan Therapy 
by European 
Commission
Automatic
Through 
hospital 
setting only
No Yes
England
Multi-Criteria 
Decision 
Analysis
<1 patient 
in 100,000-
150,000 
population 
(Under review in 
the UK)
NICE using 
MCDA 
framework
Yes Yes
Canada
Reasonable 
society cost 
of provision 
(reforms 
announced to 
include value for 
money)
NA
Special Cancer 
Fund
Applications 
must be 
made 
through 
cancer 
specialists 
No (but 
reforms 
announced to 
include value 
for money 
going forward)
Yes
Ontario
Multi-Criteria 
Decision 
Analysis
<1 patient 
in 100,000-
150,000 
population
Drugs for 
Rare Diseases 
using MCDA 
framework
No, separate 
consideration 
of cost and 
effectiveness
Yes
South Korea
Reasonable 
society cost of 
provision
<20,000 patients
<US$5 million 
annual import or 
manufacturing 
value
Automatic
Through 
Korean 
Orphan Drug 
Centre
No Yes
TABLE 3: INTERNATIONAL SYSTEMS COMPARED
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7.  Current and Future 
Challenges in Managing 
Rare Disease Therapies
Beyond the current policy and international comparisons there 
are a range of considerations that impact on the funding of rare 
disease therapies into the future. These challenges are considered 
further here.
Budget sustainability
The unit costs of new therapies 
for rare diseases are often high 
and alarming to potential funders; 
however these costs should be 
viewed in context. 
In 2013-14 the Australian 
Government spent $80 million 
on the LSDP,49 a small fraction 
of the $10.3 billion it spent on 
pharmaceutical reimbursement 
and the $64.5 billion spent on 
health generally [Figure 4].50 This 
represents just 0.2% of total 
Commonwealth health spending.
Data on expenditure on rare 
disease therapies allocated 
under the PBS is not available for 
analysis.
FIGURE 4: 2013-14 SHARES OF TOTAL COMMONWEALTH HEALTH SPENDING ($64.51 BILLION)
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THE GROWTH IN  
RARE DISEASE THERAPIES 
At the start of 1980s there was widespread concern 
about the lack of new therapies reaching the 
market to treat rare and life threatening conditions. 
In response, the United States led international 
reforms to encourage research and 
commercialisation of therapies for rare  
conditions with the Orphan Drug Act 1983. 
Reforms included incentives for innovation, lower 
fees for approval applications, enhanced market 
exclusivity clauses and fast tracked assessments.
The reforms worked. In the 30 years after the 
Orphan Drugs Act was passed over 400 new 
therapies for rare conditions came onto the 
US market. This compares to just 10 therapies 
granted market access in the decade prior to its 
enactment.51
Other jurisdictions such as the EU followed, 
introducing policies to encourage the 
development of so called orphan therapies for 
rare diseases. 
However, the success of the reforms in bringing 
new therapies to the market may well be their 
downfall. 
Governments have been wary of the financial 
implications of funding new therapies. 
As a result patients offered hope by the availability 
of new therapies to treat their rare conditions, 
have in many cases been denied access to those 
therapies due to Government reimbursement 
policies. 
Manufacturers are now faced with a dilemma.  
Do they continue to develop new therapies for 
rare conditions in the absence of certainty around 
the funding of those therapies when they are 
brought to market?
Any potential additional cost of funding 
rare disease therapies needs to be 
viewed in the context of providing 
Australians with lifesaving and life 
changing treatments that they would 
otherwise not be able to access under 
standard PBS criteria.
While most therapies for rare conditions 
often do not meet standard cost-
effectiveness criteria, they do provide 
some benefits to the budget that 
partially offset costs. These are in the 
form of reduced health expenditure 
including from reduced hospital 
admissions, reduced care and social 
security costs and increased economic 
activity due to reduction in disease 
related disability. These benefits are 
often overlooked and not consistently 
considered by the current process to 
determine the funding of new therapies. 
Consideration should also be given 
to patent expiry for current therapies. 
The reduced costs associated with 
patent expiry will contribute to funding 
of the costs of new entrants, while 
ensuring greater access to rare disease 
therapies. 
As recognised by the Government’s 
proposed Medical Research Future 
Fund, new treatments for rare diseases 
have the capacity to reduce future 
budget pressures and the forecast 
growth in health and social care 
expenditure more broadly.
The relatively small cost of the LSDP 
and potential of rare disease therapies 
to partially offset costs are factors that 
need to be considered in terms of 
managing overall health expenditures. 
These considerations, combined 
with ethical considerations discussed 
above, make rare disease therapies 
an inappropriate area for cuts in 
expenditure. 
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Future challenges
In addition to addressing current policy issues with 
Australia’s approach to funding therapies for rare 
diseases, reforms need to ensure that future policy 
challenges are also addressed.
The growing pressure from an ageing population 
will place significant pressure on Government health 
budgets and the capacity of the health system.
Finding new cures and treatments for diseases, 
including rare diseases, which are often 
accompanied by significant disability and high health 
and social care needs, will be an important part 
of the strategy to deal with an ageing population. 
This has been recognised by the Government’s 
proposed Medical Research Future Fund.
Furthermore, the development of new highly 
personalised treatments for diseases presents 
challenges for policy makers in funding these 
therapies. Different approaches are required to 
ensure that Australia fully benefits from these 
advances in treatment options and continues to be 
a world leader in providing access to new therapies.
Rising health care costs and  
an ageing population
The Government’s Fourth Intergenerational Report, 
now likely to be released in 2015, is likely to again 
highlight the impact of an ageing population on 
health expenditure. 
The National Commission of Audit, conducted in 
2014, identified health expenditure as one of the 
Commonwealth’s long running fiscal challenges 
[Figure 5]. 
Effectively managing growing health care costs 
is required to manage the long-term fiscal 
sustainability of the budget.
FIGURE 5: PROJECTED COMMONWEALTH HEALTH SPENDING (PER CENT OF GDP)52
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Funding new therapies for rare conditions under the 
current program will only marginally add to these 
costs, representing 0.24 per cent of the anticipated 
growth in health expenditure between 2013-14 and 
2017-18 [Figure 6].53 
Partially offsetting this growth however is the fact 
that new cost-effective therapies will increase the 
Government’s ability to pay for rising costs more 
generally and reduce the pressure on the health 
system. Effective new therapies will help reduce 
caring needs, increase work force participation and 
improve overall wellbeing of individuals. 
A narrow focus on the costs of new therapies 
ignores the benefits that can flow to the 
broader health system and the economy. 
The policy framework needs to recognise the 
broader benefits from new therapies and the 
broader value of medicines, to ensure that by 
denying therapies for rare diseases funding we are 
not compounding the challenges associated with 
an ageing population. 
Savings to indirect medical costs and productivity 
gains are not included in the current economic 
evaluations undertaken to demonstrate cost-
effectiveness to PBAC and would more accurately 
reflect the benefits of rare disease therapies.
The Government’s proposed Medical Research 
Future Fund has recognised the need to fund 
research into new therapies for rare and life 
threatening conditions. The Government’s 
announcement included that the Fund “…
will facilitate Australia maintaining a world class 
medical research sector, with access to cutting 
edge innovation and clinical breakthroughs in our 
hospitals – the underpinnings of the health system 
of the future”.54 In doing so the Government has 
identified curing and treating rare conditions as an 
important element of containing future health care 
costs.
However, funding new therapies once they are 
developed is an important part of ensuring the 
ultimate effectiveness of such research. 
Identifying and prioritising funding to provide 
certainty in access to those medical developments 
and innovation, particularly for rare disease 
patients, is needed to support that initiative. 
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Genomics
Individuals are inherently unique and respond 
differently to different treatments. Following the 
mapping of the human genome in 2003, the 
possibility of being able to tailor treatments to 
the individual, delivering more certain and better 
outcomes with fewer side effects, has emerged. 
Genomics or personalised medicines offer the 
prospect of revolutionising health treatment. 
However, frustration is growing in industry and 
clinically at the inability of current processes in 
Australia and overseas to inform funding decisions 
for these new therapies. 
There are inherent issues in determining the cost-
effectiveness of treatments that are unique to the 
individual, presenting similar issues to those that 
arise in the assessment of rare diseases.
The Australian Government’s 2009 Review of 
Health Technology Assessment recognised the 
difficulties of assessing personalised medicines 
for reimbursement decisions. This resulted in the 
Government providing improved coordination of 
applications requiring multiple HTA processes. 
However, it did not address some of the 
methodological issues with the current approaches. 
For example, while running a standard randomised 
control trial to provide the evidence of effectiveness 
for a condition with hundreds of sufferers is difficult, 
doing so for a treatment specifically tailored to 
individual characteristics is impossible.
Data is required to support the effect of a biomarker 
on the treatment effect of a therapy to inform the 
decision to reimburse the test, the therapy, both or 
neither.
Research has been undertaken on the changes 
that would be needed to provide a feasible 
assessment framework.55 There is a pressing need 
for Government to specifically consider these issues 
and develop a new approach for personalised 
medicines. 
For example, consideration could be given to the 
joint assessment by a single body of the cost-
effectiveness of the whole care pathway rather 
than separate consideration of each component. 
Not doing so will risk Australians missing out the 
significant benefit that genomics have to offer. The 
recommended National Strategy for Rare Diseases 
contained in this report would be an opportunity to 
further consider this approach.
Any effective policy framework will need to 
recognise the broader benefits from new 
therapies, to ensure that we do not compound 
the challenges associated with an ageing 
population by denying funding for therapies for 
rare diseases, and that we are ready to respond 
to technological developments.
2010 changes to the LSDP
Notwithstanding the relatively small cost of the 
LSDP, the then Government tightened the criteria for 
listing new drugs under the scheme in 2010. 
This occurred in response to a combination of the 
high average cost per patient per year of accessing 
therapies on the LSDP; concerns about the 
number of new therapies for rare diseases reaching 
the market, horizontal equity; efficiency and the 
sustainability of the program. 
Since the changes were introduced four years ago, 
only two new therapies have been approved under 
the LSDP. 
 Vpriv® for Type 1 Gaucher was listed in March 
2012 on the basis of cost-minimisation when 
compared to an existing treatment. 
 Soliris® (eculizumab), which was previously 
approved under the old criteria, was 
subsequently approved under the new criteria 
and listed on 1 January 2011.
Aside from these products, no new treatments for 
rare disease have successfully navigated the entire 
process for funding rare disease therapies since the 
reforms in 2010.
The most contentious change in 2010 was the 
inclusion of Criterion Four, which includes a 
requirement that there is acceptable evidence to 
predict that a patient’s lifespan will be substantially 
extended as a direct consequence of the use of the 
drug. 
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LSDP CRITERIA  
FOR FUNDING
THE DRUG MUST BE FOUND TO MEET  
EACH OF THE FOLLOWING CRITERIA:
1.  There is a rare but clinically definable 
disease for which the drug is regarded as a 
proven therapeutic modality, i.e. approved 
for that indication by the Therapeutic Goods 
Administration. 
2.  The disease is identifiable with reasonable 
diagnostic precision. 
3.  Epidemiological and other studies provide 
evidence acceptable to the PBAC that the disease 
causes a significant reduction in age-specific life 
expectancy for those suffering from the disease. 
4.  There is evidence acceptable to the PBAC 
to predict that a patient’s lifespan will be 
substantially extended as a direct consequence of 
the use of the drug. 
5.  The drug must be accepted as clinically effective, 
but rejected for Pharmaceutical Benefits Scheme 
(PBS) listing because it fails to meet the required 
cost effectiveness criteria. 
6.  There is no alternative drug listed on the PBS or 
available for public hospital in-patients, which can 
be used as lifesaving treatment for the disease. 
However, the availability of an alternative drug 
under the LSDP does not disqualify the proposed 
drug from consideration for the LSDP. 
7.  There is no alternative non-drug therapeutic 
modality (e.g. surgery, radiotherapy) which is 
recognised by medical authorities as a suitable 
and cost effective treatment for this condition. 
8.  The cost of the drug, defined as the cost per dose 
multiplied by the expected number of doses in a 
one year period for the patient, would constitute 
an unreasonable financial burden on the patient 
or his/her guardian.
The subjective nature of Criterion Four 
has created uncertainty in the industry, 
with clinicians and for patients. There is 
inherent ambiguity in the requirement 
that the therapy offer a substantial 
extension to life. This is highlighted by 
the Department of Health’s response 
to a question on notice from Senator 
Boyce in 2013 asking for the definition 
of ‘substantial’:
“Each application is assessed on its 
merit based on the strength of clinical 
evidence which is submitted by the 
pharmaceutical company, tailored to 
the specific disease.”56 
The ambiguity has created uncertainty, 
and therefore risk, for companies and 
patients seeking to gain reimbursement 
for new therapies and ensure ongoing 
access to treatment.  
The term acceptable evidence similarly 
implies a degree of subjectivity that did 
not exist previously. 
Small patient populations make it 
difficult to enroll large numbers of 
patients into standard randomised 
control trials for rare disease drugs.  
As a result, clinical trials must be based 
on smaller groups, unlike as is the case 
for more common conditions, and 
it is not at all clear what constitutes 
acceptable evidence in this context. 
For patients with rare diseases to 
not be discriminated against, a more 
flexible approach is needed.
The tightening of criteria for listing 
new rare disease therapies also raises 
questions of procedural fairness 
and the need for transparency in 
processes, discussed above as part 
of the ethical considerations of rare 
disease management.
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Implications of the 2010 reforms
Since the 2010 changes, there has been an 
increasing reliance on listing rare disease therapies 
under the PBS highly specialised drug program, 
which does not fully take into account the special 
nature of therapies for rare diseases. This has led 
to delays in patients accessing new therapies and 
created a significant administrative burden. 
Patients have had to increasingly rely on 
compassionate access from pharmaceutical 
companies to access new therapies. This increases 
uncertainty and anxiety for already vulnerable 
patients who cannot rely on ongoing access to new 
therapies.
Providing compassionate access indefinitely is 
not sustainable for pharmaceutical companies, 
which need to recoup the cost of developing new 
therapies to provide returns to shareholders and 
fund ongoing investment. 
Compassionate access schemes are not conducive 
to systematic data collection to inform practice. 
The reliance on compassionate access by 
pharmaceutical companies raises serious questions 
about the expectations of patients suffering from 
rare diseases given Australia’s otherwise universal 
health system. 
We now have the ability to treat many rare illnesses, 
but are not prioritising funding in this direction. It 
is within this context that the current review of the 
LSDP is crucial to Australian suffering from rare 
conditions.
INTERNATIONAL 
FINDINGS ON THE 
DEVELOPMENT 
OF RARE DISEASE 
MEDICINES 
Only 1 of the 5000 to 10,000 
substances initially tested 
gets through the marketing 
authorisation phase.
It is estimated that there are 
between 5000 and 8000 distinct 
rare diseases.
80 per cent of rare diseases have a 
genetic cause.
It takes on average 10 to 12 
years to develop and bring a new 
treatment to the market.
SOURCE: European Biopharmaceutical 
Enterprises and EuropaBio, Development 
process of Orphan Medicines, Available 
at: http://www.europabio.org/sites/default/
files/report/development_process_of_
orphan_medicines.pd
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8. Aligning Rare Disease 
Management 
with the National 
Medicines Policy
The Australian Government’s National Medicine Policy (NMP), 
which has four central objectives, already provides a framework to 
underpin the funding of new therapies for rare diseases.
These objectives are: 1) timely access to medicines 
at an affordable cost to individuals and the 
community; 2) that medicines should meet quality, 
safety and efficacy standards; 3) quality use of 
medicines; and 4) maintaining a responsible and 
viable medicines industry. 
While the policy for funding therapies for rare 
diseases should meet these objectives, different 
policy processes are required compared to the 
funding of other therapies under the PBS.
In this section we develop a set of policy principles 
that align with the NMP, and address the specific 
ethical and operational requirements of therapies 
for rare conditions. 
These principles can be used to assess policy 
options for the funding of therapies for rare 
diseases and the extent to which they adhere to 
the objectives of the NMP.
OBJECTIVE ONE:  
Timely access to the medicines that 
Australians need, at a cost individuals 
and the community can afford.
Cost-effectiveness
This objective of the NMP is generally interpreted as 
meaning that medicines should be demonstrated 
to be cost-effective. In keeping with this, the 2009 
LSDP review interpreted Objective One of the NMP 
as requiring evidence of cost-effectiveness in order 
to justify the funding of medicines for rare diseases.
In order to be considered for funding under the 
current program however, a drug must have failed 
to meet required cost-effectiveness threshold 
for PBS listing.57 As such, by definition, the 
current program does not meet the ‘implied’ cost 
effectiveness principle underpinning the NMP.
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For reasons described in detail in our ethics 
framework in section 7, cost-effectiveness alone is 
not a suitable metric with which to make decisions 
to fund or not to fund new therapies for rare 
diseases.
Furthermore, the cost-effectiveness criteria used by 
PBAC are relatively narrow. Benefits are generally 
limited to direct benefits for the patient and do 
not explicitly include the impact on carers. Costs 
can also be narrowly focused on healthcare costs, 
rather than taking into account broader care and 
economic costs.
Underlying the concept of cost-effectiveness used 
in the PBS is a utilitarian approach to funding. The 
often-unstated objective is to maximise health 
across the community and to do as much good as 
possible with scarce health dollars. 
On the one hand, cost-effectiveness represents 
perfect horizontal equity – it treats health gains by 
all individuals equally. However, it ignores vertical 
equity concerns about different levels of need and 
how health gains are distributed. 
The current cost-effectiveness framework places 
too much weight on a HTA method that effectively 
values extending the life of a 90 year old equally 
with that of a 1 year old.
These are inherently difficult trade-offs for society, 
practitioners, and Government. The cost-
effectiveness framework used by PBAC necessarily 
simplifies this trade-off, and as a result the 
distribution of health across the community can be 
uneven in terms of access to therapies for patients 
of rare diseases. 
Because of the small numbers of patients living 
with rare conditions a simple utilitarian approach, in 
which the greatest gain for the greatest number is 
valued highly, is unlikely to recognise the needs of 
Australians with very rare conditions. 
Difficulties faced by those with rare diseases 
include the vulnerability of small patient groups with 
limited treatment options, the nature and extent of 
the evidence, and the challenge for manufacturers 
making a reasonable return on their research and 
development investment because of the very small 
populations treated.
For solid policy reasons, cost-effectiveness alone is 
therefore not a suitable metric with which to make 
decisions to fund or not to fund new therapies for 
rare diseases.
Modifications are required in order to adapt cost-
effectiveness analyses to the funding of rare 
diseases. The standard PBS cost-effectiveness 
analysis could, for example, be explicitly expanded 
for therapies for rare diseases to include impact 
on carers, broader community care and economic 
costs.
Enriching cost-effectiveness in this way would 
better inform decision makers on the true costs of 
listing or not listing new drugs for rare diseases.
Budget sustainability 
As with any health technology, the cost of funding 
therapies for rare diseases needs to be sustainable 
within the broader health and social welfare budget. 
Unlike the criteria for general PBS listing, the 
current criteria for funding a new therapy under 
the LSDP does not refer to the budget cost 
to list a new therapy. However in the current 
fiscal environment arguably all expenditures are 
increasingly under the scrutiny of governments. 
However, as explained previously, while per unit 
costs of drugs for rare diseases are generally higher 
than other medicines funded under the PBS, small 
patient populations mean that the total budget cost 
is often relatively low. 
The current budget cost of the LSDP is 
approximately $80 million within the context of a 
$64.5 billion health budget.
Notwithstanding this small relative cost, the cost 
of funding therapies for rare diseases needs to be 
sustainable within the broader health and social 
welfare budget. 
Furthermore, a narrow focus on the budget impact 
of funding therapies for rare diseases ignores the 
broader economic and social costs of not providing 
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access to new therapies for those suffering rare 
and life threatening conditions. For example, it 
provides no consideration of the impact on the 
carers of those with rare conditions (both quality of 
life and economic loss).
Providing early access to new therapies has the 
capacity to reduce long-term care needs and 
costs, reducing budget pressures elsewhere in the 
system, and these factors should be included in 
any assessment of new therapies. 
Similarly, we have seen in the context of the 
National Disability Insurance Scheme, an 
appreciation of the lifelong cost of disability, and the 
importance of early intervention, and these factors 
apply equally to drugs for rare diseases.
While such an expansion will not make the funding 
of many therapies for rare diseases cost-effective at 
a whole population level, it will better reflect the true 
cost of providing Australians suffering rare diseases 
access to life saving and life changing treatments.
OBJECTIVE TWO:  
Medicines meeting appropriate 
standards of quality, safety and 
efficacy.
Both the Therapeutic Goods Agency (TGA) and 
PBAC require evidence on quality, safety and 
efficacy in order for drugs for rare diseases to gain 
access to the Australian market and be funded. 
However, there will always be differences in the 
quality of this evidence between therapies for 
rare diseases and therapies for more common 
conditions.
Assessing effectiveness
A number of issues make it difficult to obtain good 
quality evidence on the effectiveness of drugs for 
rare diseases compared with therapies for more 
common conditions. 
First, it is often not possible to recruit an adequate 
sample size to test treatments for very rare 
diseases through gold standard randomised control 
trials. For example, a trial of itraconazole for the 
prevention of severe fungal infection in children and 
adults with chronic granulomatous disease, took 10 
years to recruit just 39 patients.58 
Second, drug trials for rare diseases are often 
halted early on ethical grounds when interim 
analysis demonstrates clinical superiority on an 
outcome measure such as survival. In such cases, 
continuing with a placebo group would be deemed 
unethical.
Third, the clinical evidence on drugs for rare 
diseases is often based on short-term surrogate 
outcomes rather than long-term effectiveness. 
Heterogeneity of some of the conditions means 
finding populations with same clinical base lines is 
also challenging.
As a result, extrapolation and modeling of clinical 
outcomes is often used in submissions for listing 
to estimate the long-term benefits and cost-
effectiveness of therapies for rare diseases. This 
creates uncertainty around actual outcomes.
There is currently no rare disease registry or 
rare disease policy in place, making it difficult to 
effectively co-ordinate clinical trial sites in Australia. 
The development of national or international drug 
and disease registries that allow long-term follow-
up on safety and effectiveness would go part way 
to addressing these issues. 
The utility of these registers is, however, limited 
by lack of comparator groups, small patient 
populations within countries, and different 
approaches and requirements across different 
jurisdictions. It can also be difficult to identify 
patients due to misdiagnosis and require long 
time frames to produce meaningful data sets for 
analysis. 
A more coordinated approach across countries, 
focused at the disease level would better 
alleviate Government concerns. International 
disease registries for rare conditions would 
provide a broader study population, enhancing 
MCKELL INSTITUTE  |  Funding Rare Disease Therapies 
ENSURING EQUITABLE ACCESS TO HEALTH CARE FOR ALL AUSTRALIANS 45
the reliability of findings. They may also provide 
comparator treatment groups to better evaluate the 
effectiveness of the particular therapy of interest. 
Australia, as a world recognized leader in HTA, is in 
a good position to lead such efforts through bodies 
such as the World Health Organisation Department 
of Essential Medicines and Health Products.
Notwithstanding the development of such 
registries, is it important to recognise that 
differences in levels of evidence on clinical 
effectiveness for therapies for rare diseases, versus 
more prevalent conditions, are to be expected. 
This could be formally acknowledged by the 
Government being more willing to accept the 
best available evidence when assessing the 
effectiveness of new therapies for rare diseases. 
OBJECTIVE THREE:  
Quality use of medicines.
To ensure value for money, the system developed 
to fund new therapies for rare diseases should 
continue to ensure that only those patients that will 
benefit from treatments have access.
However, Australia continues to lack a holistic rare 
disease strategy, to tie together the different levels 
of government and health care provision.
All EU countries under the direction of the European 
Commission have recently completed orphan drug 
strategies. These link together the need for early 
diagnosis, treatment and care options.
A national strategy led by the Commonwealth in 
consultation with State and Territory Governments, 
patient groups and industry would improve 
outcomes for all Australians suffering rare 
conditions.
Such a strategy would allow consideration of all 
the issues and costs involved in treating individuals 
with rare conditions, not just the costs of providing 
access to rare disease drugs.
OBJECTIVE FOUR:  
Maintaining a responsible and viable 
medicines industry.
Certainty about reimbursement reduces commercial 
risk and provides a more attractive environment 
for investment and innovation. It is crucial that the 
program for funding rare disease therapies into 
the future and the PBS provide a sufficient degree 
of certainty to industry through a workable and 
transparent administration framework.
Ensuring the system for reimbursement of new 
therapies for rare diseases is accountable, 
transparent, has integrity, is well coordinated, timely 
and informed is critical. The framework for funding 
rare disease therapies must be a fit for purpose 
assessment approach that takes into consideration 
all of the issues inherent in rare diseases.
The inherently higher risks associated with research 
and innovation in the development of therapies for 
rare diseases (due to lower potential returns from 
small patient groups and difficulties in establishing 
effectiveness) make a different approach to rare 
diseases necessary.
But the administration of the current program 
for rare disease therapies is falling short of these 
requirements. A process is needed that is more 
explicitly responsive to the need to promote 
ongoing industry investment in new drugs for rare 
diseases and expands existing HTA processes to 
reflect a fit for purpose approach to rare disease 
therapies.
Medical innovation
In proposing the Medical Research Future Fund, 
the Government has recognised the importance of 
medical research in containing future health care 
costs. 
Research has indicated that for every dollar 
invested in Australian health research and 
development, an average of $2.17 in health 
benefits is returned.59
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This applies equally to rare diseases and, 
furthermore, the benefits of research into rare 
diseases go far beyond the crucial task of finding 
treatments for rare diseases. 
Rare diseases are now at the forefront of 
personalised or genomic medicine, which applies 
genetic information about each patient to tailor 
treatments to individual needs. Increasingly this 
allows certain therapies to be targeted specifically 
to the best responder patient groups, to improve 
patient outcomes, minimise side effects and reduce 
costs.
While various Government policies have led to 
much greater private investment in research and 
development of drugs for rare diseases, these 
policies rely on industry being confident that, once 
developed, these therapies will be funded.
Ensuring certainty of funding for rare disease 
medications is an important corollary for the 
successful pursuit of the objectives behind the 
proposed Medical Research Future Fund, to give 
certainty to the commercialisation and utilisation of 
medical innovations. 
Administration
For a new therapy to be considered for listing under 
the current program for rare diseases it must be 
determined to not meet the PBS cost-effectiveness 
criteria. This means companies must effectively 
apply for two separate schemes, even when it is 
clear that the cost-effectiveness criteria under the 
PBS will not be met.
Therapies for rare diseases that do meet the 
cost-effectiveness criteria are generally considered 
under the PBS’s highly specialised drug program. 
The PBAC is not allowing rare disease therapies 
through to the current LSDP, but have rather kept 
them in the PBS system. This approach fails to 
address the specific issues of rare disease and 
means the objectives of rare disease policies to 
ensure access therapies for very small patient 
groups are less likely to be met.
Even when new therapies are eventually 
funded, the process can take years and multiple 
resubmissions to PBAC by industry. These delays 
result in patients being denied access to new 
therapies that may save or substantially improve 
their lives.
Having to submit applications to PBAC for a 
rejection is unnecessary red-tape and adds to 
delays in the process for considering the funding  
of rare disease therapies.
This split and time-consuming process creates 
uncertainty, time delays and inequities in access. 
A simpler and fairer system is needed, that would 
treat all therapies for rare diseases equally through 
a single process, reducing red tape and improving 
timeliness.
There are significant differences in the decision-
making approaches for funding under the PBS and 
current rare disease program.
These go beyond specific criteria and the 
application of cost-effectiveness criteria.
In order to be listed under the current rare disease 
program a new therapy must meet all eight criteria, 
and if it fails one then it is denied funding. This is an 
exceptionally high bar to jump and a major factor 
in why so few new therapies are being listed under 
the LSDP.
The process for the PBS is more weighted and 
nuanced, taking into account how a therapy 
performs against all criteria. This allows for a new 
therapy to fail to fully meet one criterion, but still be 
listed if it performs strongly against other criteria. 
Adopting a weighted approach based on broad 
community and patient values would allow a fairer 
appraisal of individual new therapies including 
their strengths and weaknesses. This would 
provide greater procedural fairness certainty to 
manufacturers and encourage the development of 
more therapies into the future to treat rare and life 
threatening conditions.
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Addressing the issues with Australia’s current 
approach to funding therapies for rare diseases and 
meeting the objectives of the National Medicines 
Policy requires a multi-faceted approach. 
Australia’s use of Health Technology Assessments 
(HTA) within the PBS has been world leading but its 
approach to funding therapies for rare diseases is 
lagging behind international best practice.
The funding of therapies for rare diseases is 
fundamentally about resource allocation: is the 
Government’s willingness to pay for economic 
efficiency and horizontal equity– treating those 
patients that maximise health gain subject to a 
limited budget – greater than the Government’s 
willingness to pay for allocative efficiency and vertical 
equity – fairness in society? 
Answering this question is complex and standard 
approaches used by the PBS for HTA need to be 
tailored to take into account the unique nature of 
therapies for rare diseases.  
Simply increasing the cost-effectiveness threshold 
for rare diseases is unlikely to be sufficient due to 
the high price point for new therapies required to 
make their development commercially viable. A 
more flexible, fit for purpose process that takes 
into account a different set of benefits or value than 
simply a cost-effectiveness threshold is needed. 
Such a system would ideally allow the evaluation of 
treatments for rare diseases on a multi-criteria basis, 
while allowing the possibility to distinguish between 
different therapies. 
In this section we outline the case for adopting Multi-
Criteria Decision Analysis (MCDA) in the assessment 
of new therapies for rare conditions. We argue that 
such system would reflect international best practice 
and better align Australia’s system with the principles 
underpinning the National Medicines Policy. 
Multi-criteria decision analysis 
The need to balance economic and ethical 
considerations in the funding of rare therapies 
involves difficult trade-offs. Decision-making 
approaches that don’t allow for the explicit weighting 
of these trade-offs give insufficient weigh to 
competing priorities. 
As argued in this report, Australia’s current 
approach, where all eight criteria for the funding 
of new therapies under the LSDP must be met 
and a number of important considerations are not 
included, fails to reflect the complexity of decision-
making and international best practice.
One approach that would reflect the complexity of 
decision-making is Multi-Criteria Decision Analysis 
(MCDA). 
9. Improving the Management 
of Rare Disease Therapies 
through Multi-Criteria 
Decision Analysis (MCDA)
Addressing the issues with Australia’s current approach to funding 
therapies for rare diseases and meeting the objectives of the 
National Medicines Policy requires a multi-faceted approach. 
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MCDA has been developed for a number of complex 
decision-making situations and applied to funding 
of new therapies for rare diseases internationally. As 
outlined in the analysis of the international context 
in Chapter 6 of this report, MCDA has recently been 
adopted by NICE in UK in its decisions around funding 
ultra-orphan drugs and represents international best 
practice. It employs the underlying philosophy of 
HTA assessment while reflecting the unique nature of 
therapies for rare diseases.
MCDA is a way of looking at complex decisions 
that are characterised by a mixture of monetary and 
non-monetary objectives, and of breaking decisions 
down into more manageable pieces. It would for 
example allow judgments to be made on individual 
criteria relevant to rare diseases such as rarity, disease 
severity or degree of uncertainty around efficacy. 
Under MCDA these individual judgments could then 
be jointly assessed to provide an overall picture for 
decision makers. 
MCDA is both an approach and a set of techniques 
that orders options from most preferred to least 
preferred. In the case of funding new therapies for rare 
diseases in Australia there would effectively be two 
primary options: to fund or not to fund a new therapy, 
with potential additional options around conditions 
attached to the funding of a new therapy.  
MCDA allows options to differ in the extent to which 
they achieve several objectives, and no single options 
needs to achieve all objectives. This more nuanced 
approach better reflects the unique nature of therapies 
for rare conditions and is more closely aligned with the 
approach adopted in the broader PBS.
ESTABLISHING MCDA:  
DETAILED STEPS FOR A SYSTEM 
TO FUND RARE DISEASES IN 
AUSTRALIA60
1.  Establish the decision context.
1.1 Establish aims of the program to fund 
rare diseases in Australia consistent 
with the National Medicines Policy, 
and identify decision makers and other 
key players.
1.2 Design the system for conducting the 
MCDA, using NICE’s new system in the 
UK to fund ultra-rare orphans and the 
PBAC process for the PBS as a basis. 
2.  Identify the process for selecting new 
therapies to be appraised.
3.  Identify objectives and criteria.
3.1 Identify criteria for assessing the 
funding of new therapies for rare 
diseases in Australia through 
consultation with patients, the public 
and industry.
3.2 Organise the criteria by clustering 
them under high-level and lower-level 
objectives in a hierarchy.
4.  ‘Scoring’: Assess the expected 
performance of each therapy against the 
criteria then assess the value associated 
with the consequences of each option for 
each criterion.
4.1 Describe the consequences of funding 
each therapy.
4.2 Score the therapies against the 
criteria.
4.3 Check the consistency of the scores 
on each criterion.
5.  ‘Weighting’: Assign weights for each 
of the criterion to reflect their relative 
importance to the decision. 
6.  Combine the weights and scores for each 
option to derive an overall value.
6.1 Calculate overall weighted scores at 
each level in the hierarchy.
6.2 Calculate overall weighted scores.
7.  Examine the results.
8.  Sensitivity analysis.
8.1 Conduct a sensitivity analysis: do 
other preferences or weights affect the 
appraisal of therapies?
8.2 Look at the advantage and 
disadvantages of funding or not 
funding therapies.
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Importantly MCDA explicitly and transparently 
provides for trade-offs between objectives, such 
as efficiency and equity, or long versus short-term 
costs. This is well suited to consideration of funding 
of rare diseases where many such trade-offs 
are required. For example, where costs today in 
funding new treatments for rare diseases may be 
partly offset by reduced spending on health and 
community care services in the future.
In MCDA, an expert panel generally defines the 
relevant decision-making criteria and their relative 
importance. In the case of the system in Australia, 
this could be done in consultation with industry, 
patients and the community.
Each criterion needs to be measurable, so that 
the degree to which a therapy for a rare condition 
attains the objective can be assessed. The scores 
on the different criteria can then be aggregated with 
a view to calculating the overall performance of the 
therapy.
Importantly for rare diseases, MCDA systematically 
considers additional criteria beyond cost 
effectiveness, such as societal preferences, equity 
and benefits to care givers, disease rarity and 
severity, rule of rescue, availability of alternative 
health technologies, impact of drug on disease, 
clinical evidence, and manufacturing complexity.
While some of these criteria are included in the 
current program for rare diseases, MCDA would 
provide a more complete and robust framework for 
consideration.
Crucially, it would mean that no single criterion 
determined the outcome of an assessment. 
Whereas currently all eight criteria must be met 
in order for a new therapy to be funded, a MCDA 
approach would be more balanced.
While detailed work and consultation would be 
required to implementing such an approach 
in Australia, the current experience of NICE 
in England could be used as a starting point. 
Steps that would be required for such a system 
in Australia are outlined above, and provide an 
overview of a potential process including the need 
for consultation to reflect community and patient 
values.
While MCDA may be viewed as a time consuming 
approach given the limited budget impact of a 
many new therapies for rare disease in Australia, it 
does comprehensively address the complexity of 
funding therapies for rare diseases, and would help 
sustainably manage the funding of drugs for rare 
diseases into the future.
Meeting policy objectives
A system using MCDA would better meet the 
National Medicines Policy objectives and align 
more closely with the economic and ethical 
considerations identified in this report than the 
current system. MCDA provides an opportunity 
for a much broader understanding of cost 
effectiveness and a more balanced decision making 
approach reflecting community values, patient 
needs and delivering greater equity in access to 
treatments. 
An MCDA approach may still result in delays in 
access for patients with rare conditions. This 
consideration needs to be weighed against the 
need to ensure ongoing sustainability of the system 
and confidence in the integrity of the process for 
funding rare disease therapies. 
Under an MCDA approach, short-term costs may 
be higher due to more new therapies being funded. 
However in the long-term, health and social care 
costs may be reduced through access to new 
drugs and treatment of rare diseases. An MCDA 
approach would also improve the viability of the 
medicines industry in Australia through providing 
greater transparency and certainty as to which new 
therapies are likely to be funded and under what 
conditions.
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TABLE 4: MEETING THE OBJECTIVES OF NATIONAL MEDICINE POLICY
Timely access to the medicines that Australians need, at a 
cost individuals and the community can afford
Medicines 
meeting 
appropriate 
standards of 
quality, safety 
and efficacy
Quality Use 
of Medicines
Maintaining 
a responsible 
and viable 
medicines 
industry
Timely 
Access
Cost-
Effectiveness
Rule of 
Rescue
Budget 
Sustainability
Current 
LSDP
LOW
Significant 
delays in 
accessing 
treatment
LOW
Cost 
Effectiveness 
does not form 
part of current 
assessment 
under LSDP
LOW
Current 
processes 
limits access 
through 
requiring that 
all 8 criteria 
are met, 
and places 
unrealistic 
hurdles for 
listing under 
Criteria Four
MEDIUM
No 
consideration 
of broader 
social and 
economic 
costs 
increases 
long term 
costs for 
treating 
and caring 
for those 
with rare 
conditions
HIGH
All therapies 
must be safe 
and effective 
by the TGA to 
be funded
MEDIUM
While access 
to the 
therapies 
funded under 
the scheme 
is linked to 
clinically 
assessed 
need, the lack 
of broader 
strategy for 
rare diseases 
potentially 
reduces 
effectiveness
LOW
Lack of 
certainty and 
transparency 
placing viability 
of ongoing 
development of 
new therapies 
and marketing 
of these 
therapies in 
Australia under 
risk
Multi-
Criteria 
Decision 
Analysis
LOW
While this 
approach 
may be 
more likely 
to provide 
access 
to new 
therapies, 
it is likely 
to continue 
to involve 
delays
HIGH
Would expand 
current criteria 
to include 
consideration 
of a broader 
concept of cost 
effectiveness
HIGH
A weighted 
approach 
to decision 
making 
would reflect 
the unique 
nature of 
rare disease 
drugs
MEDIUM
While costs 
for funding 
therapies 
for rare 
diseases may 
be higher, 
there would 
be broader 
consideration 
of the 
economic 
and social 
costs of 
funding new 
drugs
HIGH
All therapies 
must be safe 
and effective 
by the TGA to 
be funded
MEDIUM
While access 
to the 
therapies 
funded would 
be linked 
to clinically 
assessed 
need, the 
absence of 
a broader 
strategy for 
rare diseases 
potentially 
reduces 
effectiveness
HIGH
A weighted 
approach 
including 
broader 
assessment of 
the economic 
and social 
costs and 
benefits would 
provide greater 
certainty to 
industry that 
new therapies 
would be 
funded
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Funding the additional 
expenditure
One of the issues for Government funding of 
new therapies for rare diseases is managing the 
uncertain costs of new therapies.
It is not possible to know what new therapies are 
going to become available in the future and place 
additional spending pressure on the budget.
The Government’s proposed Medical Research 
Future Fund demonstrates the Government’s 
intention to support medical research and 
innovation. To maximise the benefit of this 
investment it is also necessary to have a system in 
place that will bring products developed through 
the Medical Research Fund to market. 
Development of medications won’t suffice; 
consideration needs to be given to the 
commercialization of medical innovations. 
As noted above, the very small proportion of 
current Commonwealth health expenditure 
currently allocated to rare disease therapies (just 
0.2 per cent) mean that even with a more effective 
system for funding rare disease therapies, the very 
small patient populations mean that the level of 
expenditure growth will remain low. 
Further, the small levels of expenditure required 
to effectively fund rare disease medications are 
necessary to not only ensure Australia’s health 
system continues to meet the needs of all 
Australians, but the principles of horizontal and 
vertical equity are achieved. 
Ensuring funding for rare disease medication 
into the future is critical to both the wellbeing of 
Australians suffering from rare diseases and their 
families, and the future of rare disease innovation in 
Australia. 
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These new therapies offer the prospect of saving, 
extending and drastically improving the lives of 
thousands of Australians that suffer from rare 
diseases.
However, under Australia’s current system many 
Australians will never be able to afford to access 
these treatments.
Australia’s system for funding rare disease drugs 
requires reform to better meet the needs of 
patients, Government and industry.
This report provided an overview of the policy 
context within which the current program for 
funding rare disease therapies, the LSDP, operates, 
and highlighted the special case of therapies for 
rare conditions. 
An exploration of the policy context highlighted the 
need for a more holistic approach to rare diseases 
in Australia that should be informed by a national 
strategy on rare diseases. This strategy would 
cover research, diagnosis, new therapies, treatment 
and ongoing care for those suffering from rare 
conditions.
RECOMMENDATION I:
The Australian Government should develop 
a National Strategy for Rare Diseases that 
provides a holistic approach to rare disease 
management.
The research undertaken for this report found that 
Australians with rare diseases are not only being 
denied access to new therapies funded overseas, 
they are also waiting significantly longer for access 
to new therapies. On average Australians are 
waiting between 2 – 4 years longer for access to 
government funded treatments for rare diseases 
than in comparable countries. Some medications 
remain unavailable 8 years after becoming available 
overseas.
A review of the systems of rare disease 
management in a number of comparable countries 
was also undertaken and revealed a range of 
developments in processes, definitions, evaluation 
frameworks being adopted. Australia must reflect 
global developments in rare disease management 
in the development of its strategy to ensure 
Australia remains a world leader in health policy and 
services. 
RECOMMENDATION 2: 
Australia should be mindful of international 
practice and developments when setting rare 
disease policy frameworks.
The unique circumstances of rare diseases and 
patient groups necessitate reform of the system 
for approving rare disease therapies. The current 
system for funding therapies for rare conditions is 
failing to meet the four objectives of the National 
Medicines Policy: timely access to medicines at an 
affordable cost to individuals and the community; 
that medicines should meet quality, safety and 
efficacy standards; quality use of medicines; and 
maintaining a responsible and viable medicines 
industry. 
A system that incorporates MCDA may better 
align Australia’s system with the objectives of the 
National Medicines Policy, the identified guiding 
principles and international best practice.
10. Conclusion
In many ways the future for those suffering rare diseases in 
Australia has never been brighter, with the prospect of more 
innovative therapies being discovered than ever before.
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RECOMMENDATION 3:
A more flexible analysis of cost-effectiveness 
should be adopted in the assessment of new 
therapies that balances other considerations 
such as equity, the rule of rescue, community 
values, patient needs and the long-term 
avoided costs of access to treatment. 
Consideration should be given to using Multi-
Criterion Decision Analysis as a decision-
making framework with decision weights 
based on community and patient values.
Australia is a world leader in terms of health 
services and medical innovation and the policy 
framework that supports this system must 
continue to meet patient, community and industry 
expectations for transparent, trusted and equitable 
processes. Such processes are not only necessarily 
to reflect the complexity of rare disease therapies 
but also give confidence and certainty to patients 
and the health sector. 
Australia has a significant medical research 
capacity and the Government’s support for medical 
research and innovation necessitates a process 
for rare disease management and funding into the 
future. 
RECOMMENDATION 4:
The unique nature of therapies for rare 
diseases, including small patient populations 
and the implications this has for clinical 
trials, should be recognised in the evidence 
requirements for funding. This is necessary to 
address uncertainty in current processes for 
the development and funding of rare disease 
therapies in Australia. 
Absent a fit for purpose process for rare disease 
management, involving patients, clinicians, 
community and the sector, Australia risks 
missing an opportunity to not only manage the 
cost of treatment, including through reduced 
hospitalisations and improved patient outcomes, 
but will also risk Australia’s reputation as a world 
leading health system
RECOMMENDATION 5:
The process for assessing new therapies 
for rare diseases should be efficient, fit-
for-purpose, transparent and informed 
by community and patient values. This is 
necessary to ensure the trustworthiness and 
legitimacy of decisions about funding new 
therapies for rare diseases, that
This report seeks to strike a balance in the 
economic and social values that must necessarily 
be factored into the management of rare diseases. 
The proposed ethical framework contained in 
this report seeks to address the issues of both 
horizontal and vertical equity, critical to sustainable 
access to treatment for rare disease patients. This 
approach also provides guidance for Government 
policy on the funding of rare disease therapies in 
a manner consistent with the National Medicines 
Policy objectives. 
If adopted, the recommendations contained in this 
report will ensure rare disease patients have greater 
confidence and certainty in being able to access 
the standard of care and health services that the 
majority of Australians often take for granted. This 
is a foundation of the Australian health care system 
and one the community supports being available 
to all Australians, including those living with rare 
diseases.
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ALLOCATIVE EFFICIENCY: When resources and production are arranged so 
the benefit is maximised from the available resources – in other words the health 
sector provides society with the amounts and types of health care that they most 
prefer.61
COST-EFFECTIVENESS: A type of economic evaluation that compares options 
that have a common health outcome. The output is generally displayed as cost 
per unit of effect. Unlike a cost-benefit analysis it does not require that health 
consequences be translated into dollar amounts.62
DISTRIBUTIVE JUSTICE: The distribution of societal goods, including healthcare 
benefits, in an ethically sound manner.
EFFICACY: The performance of a health care option under highly controlled 
circumstances.63 
EFFICIENCY: Making the best use of available resources.64 
EFFECTIVENESS: This refers to the performance of a health care option in the 
real world with a wide variety of providers. 
EQUITY: Fairness in the allocation of resources between individuals or groups.65 
HORIZONTAL EQUITY: The equal treatment of equals, demonstrated when 
services are equally accessible to everyone in the community with a similar level of 
need.66 
OPPORTUNITY COST: The opportunity cost is what must be given up in order 
to obtain something (i.e. the value of time or any other input in its highest value 
use).67 
RARE DISEASE: A life threatening or chronically debilitating condition that only 
affects a very small number of people in the population.
RULE OF RESCUE: The moral and psychological imperative to help those in dire 
need. More formally, the PBAC guidelines set out the criteria for a claim of rule of 
rescue that includes that no alternative exists in Australia to treat patients with the 
specific circumstances.68 
UTILITARIANISM: The doctrine that an action is right in so far as it promotes 
happiness, and that the greatest happiness of the greatest number should be the 
guiding principle of conduct.69
VERTICAL EQUITY: The unequal but equitable (‘fair’) treatment of unequals, 
demonstrated when services account for the special needs of particular groups 
in the community and adjust aspects of service delivery to suit these needs. This 
approach may be needed where geographic, cultural or other reasons mean some 
members of the community have difficulty accessing a standard service.70
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http://www.eucerd.eu/upload/file/Reports/2011ReportStateo
fArtRDActivities.pdf. Reported in the Western Austalian Rare 
Disease Strategy 2014-2018.
7. For further information on the LSDP see the Department of 
Health’s website available at: http://www.health.gov.au/lsdp
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